Hope Medicine (Nanjing) Co., Ltd
Quick facts
Phase 3 pipeline
- HMI-115 · Oncology
HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Hope Medicine (Nanjing) Co., Ltd portfolio CI brief
- Hope Medicine (Nanjing) Co., Ltd pipeline updates RSS
Frequently asked questions about Hope Medicine (Nanjing) Co., Ltd
What is Hope Medicine (Nanjing) Co., Ltd's pipeline?
Hope Medicine (Nanjing) Co., Ltd has 1 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include HMI-115.
Related
- Sector hub: All tracked pharma companies